FDA Investigator Kurt A Brorson, PhD
Kurt A Brorson, PhD has conducted inspections on 7 sites in 3 countries as of 03 May 2024. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
7
Last Inspection Date:
03 May 2024
Investigator Role:
FDA Investigation Participant
Redica ID:
Countries of Inspections:
Korea (Republic of),
United States of America,
Germany
FDA Investigators that have inspected at least one site in common with Kurt A Brorson, PhD:
Anastasia I Offordile,
Anastasia M Shields,
Anh M Lac,
Anita Narula, PhD,
Anita R Michael,
Ann L Demarco,
Ann Marie Montemurro,
Ashar P Parikh,
Azza Talaat,
Barbara J Holladay,
Barbara Janine Breithaupt,
Bo Chi, PhD,
Brenda W Uratani, PhD,
Byungja E Marciante,
Chaltu Nwakijra,
Charles R Bonapace, PhD,
Chiang Syin, PhD,
Christian D Lynch (CDL),
Christine M Whitby, CSO,
Christopher Downey, PhD,
Concepcion Cruz, Jr,
Craig D Zagata,
Cynthia A Harris, MD, RN,
Cynthia Jim, CSO,
Cynthia White,
Daniel R Azar,
Debra Bower,
Diane L Raccasi,
Doan T Nguyen, PharmD,
Donald C Obenhuber, PhD,
Douglas A Campbell,
Dr. Mark J Seaton, PhD,
Dr. Ralph M Bernstein, PhD,
Dr. Zhihao Qiu (Peter), PhD,
Dr. Zhou Chen (nmi), MD PhD,
Eliezar Ramos,
Emest F Bizjak,
Erika V Butler,
Erin L Mcfiren,
Felix Maldonado,
Gayle S Lawson,
George Pyramides,
Grace I Cortesini,
Hao Kiet D Phan,
Haoheng Yan, PhD,
Hector A Carrero,
Hyung Yul Lee,
Jacek Cieslak, PhD,
Jacqueline Mdiaz Albertini,
James M Mason,
Joan A Loreng,
John D White,
Joseph L Despins, PhD,
Julianne C Mccullough,
Julie D Bringger,
Junho Pak,
Justin A Boyd,
Jyoti B Patel, PhD,
Kalavati Suvarna, PhD,
Kathleen R Jones, PhD,
Kenneth Nieves,
Kevin A Gonzalez,
Ko U Min,
Kristen D Evans,
Kristin M Abaonza,
Kristina J Donohue,
Kristina Mjoyce Pittman,
Lakisha M Williams,
Lynette P Salisbury,
Marcelo O Mangalindan, Jr,
Marea K Harmon,
Mariza M Jafary,
Mark Brunswick, PhD,
Mary E Storch,
Matthew B Casale,
Michael F Skelly, PhD,
Michael Shanks, MS,
Michele M Falchek,
Michelle Yclark Stuart,
Mihaly S Ligmond,
Milos Dokmanovic, PhD,
Monica Commerford, PhD,
Morris Paul,
Mra Munizn,
Nebil A Oumer,
Norman K Starks,
Omotunde O Osunsanmi,
Patricia F Hughes, PhD,
Peter Adams, PhD,
Philip J Snoy,
Prabhu P Raju,
Qing Joanna Zhou, PhD,
Rachel C Harrington,
Reyes Candau Chacon, PhD,
Richard Heath Coats,
Richard Ledwidge (nmi), PhD,
Richard W Berning,
Riley C Myers, PhD,
Robert Jennings,
Robert L Hummel,
Rose Ashley,
Russell J Glapion,
Saleem A Akhtar,
Scott N Lim,
Stephanie L Shapley,
Stephanie Mangigian, MS/OSH, RN,
Steven P Donald,
Stuart W Russell,
Subramanian Muthukkumar, PhD,
Susan M Jackson,
Susan T Hadman,
Thomas E Friel,
Thuy T Nguyen, LCDR,
Toyin B Oladimeji,
Veronica Fuentes, MS,
Virgilio F Pacio, CSO,
Viviana Matta,
Vlada Matusovsky,
Walter N Lange,
Wayne E Seifert,
Yangmin Ning,
Yanming An, PhD,
Zerita White,
Zhong Li, PhD,
Zhongren Wu,
Ziyang Su, PhD
Kurt A Brorson, PhD's Documents
Publish Date | Document Type | Title |
---|---|---|
February, 2004 | FDA 483 | Janssen Biotech, Inc. - Form 483, 2004-02-11 |
March, 2015 | FDA 483 | CELLTRION Inc - Form 483, 2015-03-06 |
June, 2002 | EIR | Boehringer Ingelheim Pharma GmbH and Co. KG - EIR, 2002-06-20 |
September, 2014 | FDA 483 | Janssen Biotech, Inc. - Form 483, 2014-09-24 |
May, 2004 | FDA 483 Response | Boehringer Ingelheim Pharma GmbH and Co. KG - Form 483R, 2004-10-22 |
February, 2004 | EIR | Janssen Biotech, Inc. - EIR, 2004-02-11 |
July, 2012 | FDA 483 | BioReliance Corporation - Form 483, 2012-07-03 |
March, 2015 | EIR | CELLTRION Inc - EIR, 2015-03-06 |
May, 2004 | EIR | Boehringer Ingelheim Pharma GmbH and Co. KG - EIR, 2004-05-28 |
June, 2002 | FDA 483 Response | Boehringer Ingelheim Pharma GmbH and Co. KG - Form 483R, 2002-06-28 |
August, 2012 | EIR | WuXi Advanced Therapies Inc. - EIR, 2012-08-24 |
February, 2004 | FDA 483 Response | Janssen Biotech, Inc. - Form 483R, 2004-03-10 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more